Unjha Formulations Ltd

Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.

As of 19-Nov, Unjha Formulations Ltd is priced at 26.40, with a recent short-term performance showing a 6.02% return over one week and 9.91% over one month, significantly outperforming the Sensex. However, a sharp decline in delivery volume raises concerns about the sustainability of this price increase, and the stock has a year-to-date decline of 13.13%.

As of 13-Nov, Unjha Formulations Ltd's stock price has risen to Rs 26.99, reflecting an 8.39% increase, and has outperformed its sector significantly. Despite a recent decline in investor participation, the stock shows strong long-term growth potential with a 166.70% increase over three years.

As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.

Unjha Formul's historical performance shows fluctuating net sales, decreasing from 18.50 Cr in Mar'24 to 13.86 Cr in Mar'25, but profitability metrics improved, with profit after tax rising to 0.41 Cr and earnings per share increasing to 0.92, indicating enhanced operational efficiency.

Unjha Formul's historical performance shows declining net sales from 18.50 Cr in March 2024 to 13.86 Cr in March 2025, but profitability metrics improved, with profit after tax rising from 0.28 Cr to 0.41 Cr and EPS increasing from 0.62 to 0.92. Overall, the company faces sales challenges while demonstrating better operational efficiency.

As of 10-Nov, Unjha Formulations Ltd is seeing a price increase to Rs 25.55, up 8.26%, with strong short-term performance but declining investor participation. Despite outperforming the Sensex recently, the stock has underperformed year-to-date, indicating potential concerns for future momentum.

Unjha Formul. will declare its results on 10 November 2025.

Unjha Formul experienced a decline in net sales from 18.50 Cr in March 2024 to 13.86 Cr in March 2025, but showed improvements in profitability metrics, with profit after tax rising to 0.41 Cr and earnings per share increasing to 0.92. Overall, the company faced a challenging year with reduced sales but enhanced operational efficiency.

As of 23-Oct, Unjha Formulations Ltd's stock price is declining at 23.88, down 3.71%, and has underperformed its sector and the Sensex significantly over the past year. The stock is trading below all major moving averages, with decreased delivery volume and no positive catalysts to support its price.

Unjha Formul's historical performance shows fluctuating net sales, peaking at 18.50 Cr in March 2024 and declining to 13.86 Cr by March 2025, while profitability metrics improved slightly, with profit after tax rising from 0.28 Cr to 0.41 Cr during the same period. Overall, the company faced a challenging environment with decreasing revenues but gradual improvements in profitability.

As of 24-Sep, Unjha Formulations Ltd's stock price is rising to Rs 25.53, up 4.29%, but it has a negative year-to-date return of -15.99% and weak long-term fundamentals. Despite today's gains, the stock faces significant challenges and is trading at a premium compared to its peers.

As of 23-Sep, Unjha Formulations Ltd is priced at 25.53, showing a 1.11% increase today and trading above all key moving averages, indicating strong momentum. However, it has underperformed the market over the past week and month, with a year-to-date decline of 15.99% compared to the Sensex's gain of 5.07%.

As of 22-Sep, Unjha Formulations Ltd's stock price is 25.25, down 0.98%, with a significant decline in investor participation and weak fundamentals. Despite a slight positive return over the past week, the stock has underperformed year-to-date and raises concerns about its valuation and ability to service debt.